Clinical Trials Using Acalabrutinib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Acalabrutinib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.
Location: 13 locations
A Phase 1b / 2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b / 2, multicenter, open-label study designed to evaluate the efficacy and safety of ACP-196 in subjects with recurrent GBM who have progressed after 1 or 2 prior systemic treatment regimens.
Location: 5 locations
ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy ACP-196 and ACP 319 in B-cell malignancies.
Location: 2 locations
Study of Acalabrutinib Alone or in Combination With Rituximab in Indolent B-cell Non-Hodgkin Lymphoma
To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with Indolent B-cell Non-Hodgkin Lymphoma
Location: 2 locations
Acalabrutinib in Combination With Obinutuzumab in Relapsed / Refractory or Untreated CLL / SLL / PLL
To evaluate the safety and preliminary efficacy of acalabrutinib in combination with obinutuzumab in 4 separate cohorts of patients.
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Acalabrutinib with or without Obinutuzumab in Treating Participants with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
Location: 3 locations